Clinical trial
Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage…
NCT00317759 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00317759 |
|---|---|
| Title | Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma |
| Official title | Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | therapeutic autologous lymphocytes, fludarabine phosphate |
| Enrollment | 12 |
| Start date | May 1, 2003 |
| Completion | Oct 1, 2008 |
| First posted | Apr 25, 2006 |
| Last update posted | Oct 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: